BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25348477)

  • 1. Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy.
    Etxano J; Insausti LP; Elizalde A; López Vega JM; Plazaola A; Martínez P
    Acta Radiol; 2015 Nov; 56(11):1300-7. PubMed ID: 25348477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
    Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
    Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Pickles MD; Lowry M; Manton DJ; Gibbs P; Turnbull LW
    Breast Cancer Res Treat; 2005 May; 91(1):1-10. PubMed ID: 15868426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
    Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
    Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the reproducibility of a protocol for the pharmacokinetic study of breast tumors by dynamic magnetic resonance imaging.
    Etxano J; García-Lallana Valbuena A; Antón Ibáñez I; Elizalde A; Pina L; García-Foncillas J; Boni V
    Radiologia; 2015; 57(1):44-9. PubMed ID: 24525219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer.
    Guo W; Zhang Y; Luo D; Yuan H
    Br J Radiol; 2020 Nov; 93(1115):20200751. PubMed ID: 32915647
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
    Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
    Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer.
    Dogan BE; Yuan Q; Bassett R; Guvenc I; Jackson EF; Cristofanilli M; Whitman GJ
    Curr Probl Diagn Radiol; 2019; 48(3):235-240. PubMed ID: 29685400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
    Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
    Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of dynamic contrast-enhanced MRI perfusion parameters with angiogenesis and biologic aggressiveness of rectal cancer: Preliminary results.
    Yeo DM; Oh SN; Jung CK; Lee MA; Oh ST; Rha SE; Jung SE; Byun JY; Gall P; Son Y
    J Magn Reson Imaging; 2015 Feb; 41(2):474-80. PubMed ID: 24375840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical mammography using diffuse optical spectroscopy for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
    Schaafsma BE; van de Giessen M; Charehbili A; Smit VT; Kroep JR; Lelieveldt BP; Liefers GJ; Chan A; Löwik CW; Dijkstra J; van de Velde CJ; Wasser MN; Vahrmeijer AL
    Clin Cancer Res; 2015 Feb; 21(3):577-84. PubMed ID: 25473002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Teruel JR; Heldahl MG; Goa PE; Pickles M; Lundgren S; Bathen TF; Gibbs P
    NMR Biomed; 2014 Aug; 27(8):887-96. PubMed ID: 24840393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
    Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
    Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
    Li X; Abramson RG; Arlinghaus LR; Kang H; Chakravarthy AB; Abramson VG; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Yankeelov TE
    Invest Radiol; 2015 Apr; 50(4):195-204. PubMed ID: 25360603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study.
    Chou CP; Wu MT; Chang HT; Lo YS; Pan HB; Degani H; Furman-Haran E
    Acad Radiol; 2007 May; 14(5):561-73. PubMed ID: 17434070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI.
    Johansen R; Jensen LR; Rydland J; Goa PE; Kvistad KA; Bathen TF; Axelson DE; Lundgren S; Gribbestad IS
    J Magn Reson Imaging; 2009 Jun; 29(6):1300-7. PubMed ID: 19472387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
    Martincich L; Montemurro F; De Rosa G; Marra V; Ponzone R; Cirillo S; Gatti M; Biglia N; Sarotto I; Sismondi P; Regge D; Aglietta M
    Breast Cancer Res Treat; 2004 Jan; 83(1):67-76. PubMed ID: 14997056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
    Chen BB; Lu YS; Lin CH; Chen WW; Wu PF; Hsu CY; Yu CW; Wei SY; Cheng AL; Shih TT
    BMC Cancer; 2016 Jul; 16():466. PubMed ID: 27412562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced MRI: Use in predicting pathological complete response to neoadjuvant chemoradiation in locally advanced rectal cancer.
    Tong T; Sun Y; Gollub MJ; Peng W; Cai S; Zhang Z; Gu Y
    J Magn Reson Imaging; 2015 Sep; 42(3):673-80. PubMed ID: 25652254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.